Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Let’s not get carried away ... one step at a time people please ... and forwards please TM
Ramblings from me.
Pfizer dropped their chk1 as it didn't meet primary endpoint in ovarian. According to endpoints 5 days ago.
We are dosing at higher levels as less toxic. But srra are deprioritising. Suggests our data in ovarian is not overwhelming.
Combo data still to come
Combo with parps and wee1 looking very viable Merck. Azn . Jansen in the mix
Srra has limited cash.
And a pathway to fast track in anogenital but srra dont want to front a 20m milestone for a subset of indications. I dont know how this will play out. But obviously on the radar/involved with several big pharma. My expectation is sublicences. Azn for a wee1 combo. Merck for a keytruda combo. Jansen for a niraparib in breast. And crt to cofund an anogenital trial. But as usual I may be blowing smoke up my own arse for which I apologise
Thoth2 - how long from expression of interest to conclusion of sub-licence deal? Presumably the lawyers involved are doing these deals all the time. For Sierra there must be a real urgency given gone potentially imminent Nasdaq delisting.
Thoth. What is your thoughts on target price?
Hi Krone - this is an interesting read on Pharma deals.
https://cdn.ymaws.com/www.michbio.org/resource/resmgr/BioToolBox_-_Commercialization/Bio_Pharma_Partnering.pdf
Stoney - many thanks, really interesting and informative.
In the context of Sierra and 737 one would expect Nick Glover to be well versed in the licencing process and to have been getting his ducks lined up for some time....given the November Nasdaq deadline if the non-dilutive options have not been set up by then Sierra will be in deep misery.
In respect of Sareum, if the CHK1 deal negotiations were handled by CPF/CRT with Sareum on the periphery their experience will be limited which may not bode well for TYK2. I have real anxiety that we are going to at worst fail or at best not fully realise the value of 1801/2 due to lack of experience/expertise. Tim and John are clearly very capable scientists and have invested many years in getting Sareum to where it is today however they probably don't have the business acumen necessary to bring the baby home. Parker is along for the ride and is more focussed on MGC Pharmaceuticals, Glyndebourne, Brexit and Surrey carpet bowls association, Michael Owen is 67 and probably winding down, Clive Birch is 65....
I'm convinced the NEDS are here to help wind down the company. The age of the NEDS is another pointer IMO. Runoff mode is the term Thoth used, an insurance term but I get what he meant. They may be helping to secure a deal but being non-execs they are perfectly placed for caretaking roles. Target price and date is anyone's guess but I still believe getting a CHK1 milestone will be the catalyst to get things moving. This is the reason, IMO, that we won't get the true value for the TYK2 compounds. It's too early to sell TYK2 but we have taken as far as we can. Once TYK2 is in P1, it'll be time to start the wind-down.
In my opinion age has nothing to do with it, f they have the experience and nous they can broker any sized deal. In regards to licensing Tyk2 pre-clinical it can still achieve a large deal as Tyk2/JAks are becoming more popular since the Celgene deal earlier this year. If I remember correctly Tim mentioned a pre-clinical deal for a company in the US for $800m in a proactive investor interview and has been gunning for something similar ever since- the finals RNS I believe was Sar's confirmation of the type deal(s) they want and I think they are now looking at billions, but what do I know, I can only read between the lines like everyone else. The Chk1 milestone for sure will be a catalyst for the share-price no doubt but also security for Sar to fight for a bigger deal as they will have the funds to further validate Tyk2 even take it to ph1.
What I mean about their age is this isn't a long term plan.
Potnak, I agree. It very much seems like an endgame scenario, especially as they do not seem to be showing any interest in producing anything further from the SKIL Platform.
Tim has stuck his head above the parapet and said significant value within 12 months. Only 9 months to go. He's been burnt before with this sort of thing. Hopefully, he believes the statement to be true this time.
Tim has actually indicated 'significant value' three times since March 2019
26/6/2019 - We believe we have the potential to generate significant value with these candidates, which represent exciting prospects in an area of increasing interest in the pharmaceutical industry.
13/6/2019 - We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes.
4/3/2019 - advancing these two programmes as quickly and as rigorously as possible is the focus of all our current resources and we are convinced that they offer the potential to generate significant value for shareholders.”
I won't hold him to the timescale exactly because I believe we'll put TYK2 in P1 before anything big happens. I guess by next June, we will know when the trails are staring? And hopefully be flush with milestones.
Being pedantic Tim does say ‘over’ the next 12 months which may suggest a series of value increases as opposed to a single event?
Krone, I wouldn't hold these words to account, his favourite word before that was transformational...
Yet we look to be the inverse of that.
I'll hold and add when available until TYK2 data published.
GLA
Maybe I was optimistic and should have said “roll on the 0.5p party first” ... given the attitude of the MMs dropping this by 6% on little volume in the last few days ....
Sometimes I think I am on a different board to the share!
Arghhhh ... how low can we go ... roll on the 0.4p party
Unfortunately I can see the next update already..... 'We have delivered significant value to shareholders with the SP having doubled from 0.2p to 0.4p. This is a transformational change and shows real progress in our drive to deliver a best in class, last in the market product. We continue to hold conversations with global pharmaceutical companies but none of them are talking back to us. In the meantime I am pleased to announce another placing of 500m shares which after costs and salaries has placed a net 2 shillings and sixpence in the companies bank account'. Please tell me it was just a bad dream....
It not a bad dream- It's a bloody nightmare on elm street with kruger posing as parker. No one ever said pharma was short-term investment- for me the silence has all the hallmarks of the silence leading up to the Chk1 licencing deal albeit with Tyk2 100% owned and a potentially bigger market as the recent Celgene deal has indicated and by what Sar projected in the final RNS (i.e. the deal sizes). I take great encouragement from the fact the Pfizer's Tofa is on the market turning over $1.8bn per annum and they know that our Tyk2 is better in the RA studies they conducted and funded- so it's just a matter of time before the inevitable deal lands.
Just out of interest has anyone purchased and read the full publication of T.Sen at MD Anderson SCLC, I purchased and have had a good read, wondering how many people here has read it, cost was £29 roughly!
I was dreaming of 28p. Unfortunately the nightmare of .38p is a lot closer.
Still waiting.
KR
ZA
RMM-very droll!!
Unfortunately bit too close to reality for comfort.
Tim & Co are doing a Blackadder in the trenches well behind the parapet hoping the probable forthcoming assault by shareholders will not happen. How long before Parker turns and runs I wonder.
https://quoteddata.com/2019/07/trust-favourite-gilead-expands-deal-galapagos/
note the last sentence.. why not partnered. molecule no good. business development useless. or we dont need the cash and would rather have another dilution. Ill do the emails this weekend as I have less on then.
Emails are out to opt out or opt in. Pls respond over weekend. All opted in so far end enough votes to Muller any motion. It is our company and the executive operate at our direction. Just need to organise which we have. A parliament Brexit government analogy but we own the company and will not be taken for fools